

Clatterbridge Road Bebington Wirral CH63 4JY

Tel: 0151 556 5000 Web: www.clatterbridgecc.nhs.uk

Date: 24 September 2019

Re: Freedom of Information Request

Ref: 251 - 2019

Thank you for your email dated the 10<sup>th</sup> September 2019, requesting relating to patients being treated for multiple myeloma or chronic lymphocytic leukaemia.

The information that you require is as follows:

In accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

This is a freedom of information request relating to patients being treated for multiple myeloma or chronic lymphocytic leukaemia.

1. Does your trust treat adult multiple myeloma [MM]? - if you refer your multiple myeloma patients to another centre, please state which.

Yes the Trust does treat adult multiple myeloma [MM]

- 2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
  - Bortezomib [Velcade] = 7

- Carfilzomib [Kyprolis] = 0
- Ixazomib [Ninlaro] = 13
- Lenalidomide [Revlimid] = 28
- Daratumumab [Darzalex] Exempt under Section 40: Personal Information
- Melphalan, prednisolone and thalidomide (known as MPT)
   Exempt under Section 40: Personal Information
- Cyclophosphamide, thalidomide and dexamethasone (known as CTD) Exempt under Section 40: Personal Information
- Pomalidomide [Imnovid] Exempt under Section 40: Personal Information
- 3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?

  Over the past 6 months, 28 chronic lymphocytic leukaemia (CLL) patients have been treated

If possible, how many CLL patients treated were new to therapy in the past 3 months?

Exempt under Section 40: Personal Information

- 4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
  - Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR) = 0
  - Bendamustine and rituximab (known as BR) = 0
  - Ibrutinib [Imbruvica] = 9
  - Chlorambucil Exempt under Section 40: Personal Information
  - Venetoclax Exempt under Section 40: Personal Information
  - Obinutuzumab Exempt under Section 40: Personal Information
  - Idelalisib= 0
  - Fludarabine and rituximab (known as FR) = 0
  - High-dose prednisone and rituximab= 0
  - Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) = 0
  - Alemtuzumab (Campath) with rituximab= 0

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

Version: 1.0 Ref: ECGMFOIRE If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Version: 1.0 Ref: ECGMFOIRE